ATI 502

Drug Profile

ATI 502

Alternative Names: A 301; ATI 50002; ATI-502

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer Aclaris Therapeutics
  • Class Skin disorder therapies
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia areata; Vitiligo

Most Recent Events

  • 23 Mar 2018 Aclaris Therapeutics has patent protection for ATI 502 in the US and pending applications in USA, Australia, Canada, European Union and Japan
  • 12 Mar 2018 Aclaris Therapeutics plans a phase II open-label trial for Alopecia (Androgenetic alopecia) in the first half of 2018
  • 19 Dec 2017 Phase-II clinical trials in Vitiligo in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top